AzTrials
AzTrials

Post COVID-19 ConditionNCT05950230

Periodontal Health in Post COVID-19 Patients

An observational study of Post COVID-19 Condition, run by Ain Shams University.

Unknown status

Status not confirmed. The sponsor has not verified this record for over two years, so it may be out of date.

Official record
Search all trials

Trial summary

The aim of this study is; To Assess the association between periodontal health and Matrix metalloproteinase-8 (MMP-8) level in Gingival Crevicular Fluid (GCF) in post COVID-19 patients. Read more about this study

Who is it for?
Ages 25 to 60 years
Conditions the study is for
Post COVID-19 Condition
What is being tested?
Assess Periodontal Health Status and Collecte GCF samples by paperstrip
How many people
90 participants
Where
No sites listed yet
Study dates
1 Aug 2023to 1 Dec 2023
Phase
Observational
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 25 to 60 years
  • All sexes
  • Adult

Study population: Case Group (Post-SARS-CoV-19) willinclude (n = 45) patients met the previous criteriaand had undergone (rRT-PCR) for the diagnosis of COVID-19 and recovered from all symptoms and finished isolation period or had negative rRT-PCR after infection(Yong, 2021, Marvisi et al., 2020, Liao et al., 2021, guidelines, 2021). Control Group (Non-SARS-CoV-19) willinclude (n = 45) patients met the previous criteria with no records of COVID-19 infection or suspicious symptoms.

Who may be able to join

  • Both genders aged from 25-60.
  • Systemically free(According to Cornell Medical Index-Health Questionnaire)(Pendleton et al., 2004).
  • Having at least 20 teeth excluding third molars.
  • Performing regular oral hygiene instructions.
  • Patients with a current laboratory-confirmed SARS-CoV-2 infection after recovery time form Coronavirus who isolated themself at home (according to the Centers for Disease Control and Prevention (CDC) guidelines) until all of these things are true:(Jeong et al., 2021).
  • Haven't had a fever for 24 hours without using a fever-reducing medicine.
Show all 10Show fewer
  • Symptoms are better, though they might not be totally gone.
  • It's been at least 10 days since their symptoms started.
  • Note that these recommendations do not apply to people with severe COVID-19 or with weakened immune systems (immunocompromised).
  • For people who are asymptomatic (never develop symptoms): Isolation and precautions can be discontinued 10 days after the first positive viral test(Jeong et al., 2021).

Who cannot join

  • Smoking and Smokeless tobacco use.
  • Patients suffering from post-covid permanent complications (lung fibrosis- Mucormycosis, …...) in cases group.
  • Patients having gingivitis.
  • Status of pregnancy, lactation.
  • Obese patients.
  • Patients who have undergone any periodontal therapy in the last 6 months.
  • Vulnerable groups of patients' e.g. (prisoners, handicapped patients and orphans).

Trial locations and contacts

No sites are listed yet.

RANDA N. ALZOUBI, Master contact

1554391506 ext. 0020

RANDAALZOUBI@dent.asu.edu.eg

Yasmine A. Fouad, Lecturer contact

1005793929 ext. 0020

About this study

Official title: A Case-Control Study on the Association Between Periodontal Health and Gingival Crevicular Level of Matrix Metalloproteinase-8 in Post COVID-19 Patients

The aim of this study is; To Assess the association between periodontal health and Matrix metalloproteinase-8 (MMP-8) level in Gingival Crevicular Fluid (GCF) in post COVID-19 patients.

Read the detailed description

Periodontitis is a serious problem disease due to its extensive prevalence. The most common definition of Periodontitis is a chronic inflammatory disease associated with many factors linked with plaque formation and characterized by the first clinical sign which is clinical attachment loss (CAL) and alveolar bone loss in a radiograph.

Initiation of periodontitis and progression depends on dysbiotic changes in the gingival sulcus microbiome in response to inflammation which activates of many molecular pathways, that result in loss of marginal periodontal ligament fibers, and apical migration of the junctional epithelium, which allows the bacterial biofilm to diffuse apically along the root surface.

Periodontitis is dependent on a number of origins but the main responsible is the dental plaque, While the progression is affected by the host response to local factors like plaque and calculus, genetics, environmental factors, systemic health, lifestyle habits, and various social determinants also play a role.

The etiology of periodontitis is the host periodontal tissues exposure to oral bacteria (including polymicrobial synergy, viruses, fungi, and parasites) that accumulate in oral biofilms, known as dental plaque, due to a lack of appropriate oral hygiene, which refers to a proper environment to retract inflammation products as polymorphonuclear, neutrophils, pro-inflammatory cytokines, matrix metalloproteinases, and reactive oxygen species, leading to gingivitis, when it is not treated well; a host immune system response is triggering progressing to periodontitis, in this case, other factors will act as progression more important than dental plaque, that means periodontitis is polymicrobial, multifactorial disease.

In a healthy periodontium, there is a microbial balance in the biofilm but when this balance is lost, increasing acid-producing concentrations and acid tolerating bacteria is a result in dental biofilm.

The process of this inflammatory imbalance activated by Porphyromonasgingivalis (Pg), Aggregatibacteractinomycetemcomitans (Aa), Tannerella forsythia(Tf), and Treponema denticola (Td) resulting from uncontrolled host immune response, this inflammatory process composed of 4 elements : (1)Bacteria, viruses, fungi, parasites, and cell damage, toxic cellular components, or any other harmful condition which is molecular patterns associated with pathogens(PAMP) and damage (DAMP); (2) cellular receptors that recognize these molecular patterns (PRR); (3) cytokines, chemokines which are proinflammatory mediators.; and (4) cells and tissues which proinflammatory mediators are targeting.

A set of inflammatory markers such as cytokines, like Tumour Necrosis Factor-α (TNF-α), Interleukin (IL)-1β, IL-4, IL-6 and IL-10, interleukin-17,serum C - Reactive Protein (CRP), prostaglandin E2 , Serum Ferritin,matrix metalloproteinases (MMPs), neutrophil collagenase, also known as matrix metalloproteinase-8 (MMP-8) and gelatinase B, also known as matrix metalloproteinase-9 (MMP-9)have high levels in periodontal disease, and specificallyelevatedactive Matrix metalloproteinase-8(MMP-8) in gingival tissue, saliva, and Gingival Crevicular Fluid (GCF) was the point of present for the early diagnosis of periodontitis.

The name of matrix metalloproteinases (MMPs) is derived from members of an enzyme family that are essential for preserving tissue allostasis and contribute to the normal turnover of periodontal tissues, they are also responsible for extracellular matrix proteins degradation during periodontitis. There are more than 20 members in the MMPs such as MMP-2, MMP-8, MMP-9, and MMP-13, Among them, MMP-8 is the most important collagenase in periodontitis; on top of that, MMP-8 is responsible for 90% to 95% of collagenolytic activity in gingival crevicular fluid. that is why MMP-8 is now considered one of the most promising diagnostic biomarkers for periodontitis in oral fluids, and proposed no or limited false positives comparing with traditionally used clinical examination as bleeding on probing.

Matrix metalloproteinase-8 (MMP-8; neutrophil collagenase or collagenase-2) secreted by neutrophils as a main proteolytic enzyme activated by inflammation mediators and can be used in diagnosing periodontitis and peri-implantitis.MMP-8 particularly damages two important structural components, interstitial collagens (types I-III), which is an extracellular matrix, also many pro-and anti-inflammatory cytokines, chemokines, and others that are non-matrix bioactive proteins degrade. several inflammatory cytokines, like IL-1β, TNF-α, can increase the expression of MMP-8 in inflammatory sites, in addition, T. denticola and P. gingivalis and their proteases lead to an increase in the activation of MMP-8.

Different chronic inflammatory diseases mainly periodontitis, peri-implantitis, diabetes, rheumatoid arthritis, increase MMP-8 level.

The MMP-8 test is mainly used for the assessment of periodontal health and the early detection of periodontitis and its staging, in addition to prediction of the risk of peri-implantitis and as monitoring tool during peri-implantitis treatment, while MMP-8levels might also be elevated with some inflammatory and malignant diseases like myocardial rupture, head and neck squamous cell carcinoma and breast cancer the MMP-8 test is not used as diagnostic tool for this condition as it's roll is still not fully understood.To detect MMP-8, we can use Enzyme-linked immunosorbent assay (ELISA), Time-resolved immunofluorometric assay (IFMA), MMP-8 specific chair-side dip-stick test and dentoAnalyzer device.

Gingival Crevicular Fluid (GCF) is generated from the postcapillary venules in the gingival plexus so that it brings the immune blood components to the sulcus as a function (like neutrophils, antibodies, and complement components), finding elevated secretion of GCF especially neutrophils which is an essential component in GCF reflecting inflammation state.

Collecting GCF from the gingival sulcus for analysis takes special attention in studying researches as it reflects periodontium and systemic health.In 2005 Loos and Tjoa reviewed eight periodontal inflammatory markers: alkaline phosphatase, cathepsin B, β-glucuronidase (βG), collagenase-2 (matrix metalloproteinase, MMP-8), gelatinase (MMP-9), dipeptidyl peptidase (DPP) II and III, aspartate aminotransferase (AST) and prostaglandin E2 (PGE2) and elastase enzyme .

Many studies revealed a High level of MMP-8 in GCF in chronic periodontitis patients as a diagnostic test, in association with increased activity of GCF collagenase, loss of connective tissue attachment, but after successful treatment MMP-8 level significantly decrease in GCF.

Different studies have indicated many human viruses particles in GCF : human immunodeficiency virus(HIV), herpes simplex virus (HSV), cytomegalovirus (CMV), Epstein-Barr virus(EBV), Zika virus, and currently Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) known as COVID-19, identification in GCF during nowadays pandemic, is a serious investigation of interest.

In 2020 Pfützner reported COVID-19 as a major pandemic causing severe acute respiratory syndrome. Most COVID-19 patients suffer from mild symptoms like fever, cough, dyspnea, and other respiratory complications, but it may progress to the severity condition like pneumonia or it can reach mortality in presence of aging or comorbidities as chronic lung disease, moderate to severe asthma, severe obesity, diabetes, chronic kidney disease, and liver disease, despite that many patients without comorbidities suffering from a complication of severCOVID-19 infection.

Recently, a lot of researchers gave evidence that there is a direct association between periodontal health and COVID-19 by approving that the oral cavity is a potential reservoir for the COVID-19 virus, mainly in GCF, Sub-gingival plaque biofilm, dental calculus, and saliva.

Viral particles of COVID-19 and its receptors were detected in oral fluids as Angiotensin Converting Enzyme II (ACE2), cluster of differentiation 147(CD147), and trans-membrane serine protease 2 (TMPRSS2) assist SARS-COV-2 entry to host cells, also TMPRSS and furin contribute to spreading the infection by cleaving the virus S protein of COVID-19 virus.

Assessment of periodontal health in patients helps in determining risk factors during and after the pandemic along with encouraging the need to maintain oral and periodontal health, as we as dental practitioners to be aware of the way of transmission even during non-surgical periodontal therapy.

In2021Pradeep et al.,proved that periodontitis severity is higher in COVID-19 patients than noninfected, they examined periodontal health by recording plaque index, calculus amount, tooth mobility, gingival bleeding, probing depth, recession and clinical attachment level, they indicated that all people should maintain their oral hygiene as one of the prevention methods of COVID-19 infection.

In a clinical study aiming to link between Periodontitis and COVID-19 MMP-8 levels in saliva and GCF was high in patients with periodontal disease and COVID-19, and interestingly some periodontal healthy patients showed an elevation of MMP-8 levels during their infection with COVID-19, which the authors related to the cytokine storm associated with COVID-19.

Because of association between MMP-8 and the tissue destruction in periodontitis/peri-implantitis diseases, it is known that this enzyme is abnormally elevated in COVID-19 patients in a response to cytokine storm related to COVID-19 infection(Sorsa et al., 2021).

As recommended by Ismoet al.,2020, in response to the relation between periodontitis and COVID-19 infections, MMP-8 test could possibly also help estimate the risk of periodontium damage and complications.

In our point of view this increase in MMP-8 levels could be associated with some long term complications of periodontal health after recovering from COVID-19 even for the periodontal healthy patients.

No assessment study has been carried out on the Egyptian population to evaluate periodontal health in post-COVID-19 patients, and none of the published literature worldwide correlated periodontal status and MMP-8 level in GCF for post-COVID-19 patients compared with none previously infected patients.

Thus, the present study was be carried out to assess the periodontal status in post-COVID-19 patients and examine MMP-8level in their GCF to investigate the links between post COVID-19 infection periodontal health and MMP-8 level.

Being tested
Assess Periodontal Health Status, Collecte GCF samples by paperstrip
Keywords
Periodontal health, Gingival Crevicular Fluid (GCF), Matrix metalloproteinase-8 (MMP-8)

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • Assess Periodontal Health StatusDiagnostic test

    For all patients who are suitable for the study, the following clinical evaluation parameters will be recorded:

    • Plaque index (PI)(Silness and Löe, 1964).
    • Sulcus bleeding index(BOP)(Perez et al., 2008).
    • Probing depth (PD) (Polson et al., 1980).
    • Clinical attachment level (CAL) (Glavind and Löe, 1967).
    • Standardized Periapical Radiograph.
  • Collecte GCF samples by paperstripOther

    GCF samples will be collected from all participating individuals to assess the levels of MMP-8 from the deepest periodontal pocket in the area. The sample areas will be insulated with cotton rolls, saliva contamination will be prevented, all supragingival plaque will be eliminated. The paper strips will placed into the periodontal pocket until resistance is felt and then permitted to remain for 30s(Offenbacher et al., 1984, Megson et al., 2010).

Study groups in NCT05950230
Study groupRoleWhat they receive
Cases45 Patients with history and results of recovered COVID-19 infection.
Receives: Diagnostic Test: Assess Periodontal Health Status; Other: Collecte GCF samples by paperstrip
Control45 Patients with negative history of COVID-19 infection.
Receives: Diagnostic Test: Assess Periodontal Health Status; Other: Collecte GCF samples by paperstrip

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Clinical Assessment

    Complete periodontal examination including the dentition status, numbers of present teeth, carious teeth, and missing teeth which including absent or indicated for extraction because of periodontal disease, and wasting diseases, such as abrasion and were recorded, followed by the recording of plaque scores, tooth mobility, gingival bleeding, probing depth (PD), recession (REC), and clinical attachment level (CAL) at six sites per tooth in all the teeth apart from the third molars using a unc-15 periodontal probe.

    Measured: Baseline

  2. Biochemical Assessment

    Each GCF sample will be evaluated forMMP-8 level using commercially available ELISA kits in accordance with the manufacturers' instructions.

    Measured: Baseline

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted18 Jul 2023
  2. Study start1 Aug 2023 (estimated)
  3. Primary completion1 Nov 2023 (estimated)
  4. Study completion1 Dec 2023 (estimated)

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Observational
Observational model
Case-control
Time perspective
Retrospective
Enrolment
90 participants (estimated)
IDs, dates and publications
ClinicalTrials.gov ID
NCT05950230
Sponsor's protocol ID
Post COVID19
Status last verified
Jul 2023
First submitted
14 Jul 2023
Last updated
18 Jul 2023
Results posted
No
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
No

Publications

  • Acharya AB, Thakur S, Muddapur MV, Kulkarni RD. Cytokine ratios in chronic periodontitis and type 2 diabetes mellitus. Diabetes Metab Syndr. 2017 Oct-Dec;11(4):277-278. doi: 10.1016/j.dsx.2016.12.007. Epub 2016 Dec 13.

    PubMed 27989515
  • Anand PS, Jadhav P, Kamath KP, Kumar SR, Vijayalaxmi S, Anil S. A case-control study on the association between periodontitis and coronavirus disease (COVID-19). J Periodontol. 2022 Apr;93(4):584-590. doi: 10.1002/JPER.21-0272. Epub 2021 Aug 24.

    PubMed 34347879
  • Bansal T, Pandey A, D D, Asthana AK. C-Reactive Protein (CRP) and its Association with Periodontal Disease: A Brief Review. J Clin Diagn Res. 2014 Jul;8(7):ZE21-4. doi: 10.7860/JCDR/2014/8355.4646. Epub 2014 Jul 20.

    PubMed 25177663
  • Berton F, Rupel K, Florian F, Biasotto M, Pallavicini A, Di Lenarda R. Dental calculus-a reservoir for detection of past SARS-CoV-2 infection. Clin Oral Investig. 2021 Aug;25(8):5113-5114. doi: 10.1007/s00784-021-04001-8. Epub 2021 May 26. No abstract available.

    PubMed 34037853
  • Campisi G, Bizzoca ME, Lo Muzio L. COVID-19 and periodontitis: reflecting on a possible association. Head Face Med. 2021 May 11;17(1):16. doi: 10.1186/s13005-021-00267-1.

    PubMed 33975613
  • Casillas Santana MA, Dipp Velazquez FA, Samano Valencia C, Martinez Zumaran A, Zavala Alonso NV, Martinez Rider R, Salas Orozco MF. Saliva: What Dental Practitioners Should Know about the Role of This Biofluid in the Transmission and Diagnostic of SARS-CoV-2. Medicina (Kaunas). 2021 Apr 6;57(4):349. doi: 10.3390/medicina57040349.

    PubMed 33917276
  • Chakraborty S, Tewari S, Sharma RK, Narula SC. Effect of non-surgical periodontal therapy on serum ferritin levels: an interventional study. J Periodontol. 2014 May;85(5):688-96. doi: 10.1902/jop.2013.130107. Epub 2013 Jul 4.

    PubMed 23826646
  • Czumbel LM, Kiss S, Farkas N, Mandel I, Hegyi A, Nagy A, Lohinai Z, Szakacs Z, Hegyi P, Steward MC, Varga G. Saliva as a Candidate for COVID-19 Diagnostic Testing: A Meta-Analysis. Front Med (Lausanne). 2020 Aug 4;7:465. doi: 10.3389/fmed.2020.00465. eCollection 2020.

    PubMed 32903849
  • Fatemi K, Rezaee SA, Banihashem SA, Keyvanfar S, Eslami M. Importance of MMP-8 in Salivary and Gingival Crevicular Fluids of Periodontitis Patients. Iran J Immunol. 2020 Sep;17(3):236-243. doi: 10.22034/iji.2020.81170.1512.

    PubMed 32996900
  • Glavind L, Loe H. Errors in the clinical assessment of periodontal destruction. J Periodontal Res. 1967;2(3):180-4. doi: 10.1111/j.1600-0765.1967.tb01887.x. No abstract available.

    PubMed 4237475
  • Gomes SC, Fachin S, da Fonseca JG, Angst PDM, Lamers ML, da Silva ISB, Nunes LN. Dental biofilm of symptomatic COVID-19 patients harbours SARS-CoV-2. J Clin Periodontol. 2021 Jul;48(7):880-885. doi: 10.1111/jcpe.13471. Epub 2021 May 4.

    PubMed 33899251
  • Griffiths GS. Formation, collection and significance of gingival crevice fluid. Periodontol 2000. 2003;31:32-42. doi: 10.1034/j.1600-0757.2003.03103.x. No abstract available.

    PubMed 12656994
  • Gupta S, Mohindra R, Chauhan PK, Singla V, Goyal K, Sahni V, Gaur R, Verma DK, Ghosh A, Soni RK, Suri V, Bhalla A, Singh MP. SARS-CoV-2 Detection in Gingival Crevicular Fluid. J Dent Res. 2021 Feb;100(2):187-193. doi: 10.1177/0022034520970536. Epub 2020 Nov 2.

    PubMed 33138663
  • Gupta S, Mohindra R, Singla M, Khera S, Sahni V, Kanta P, Soni RK, Kumar A, Gauba K, Goyal K, Singh MP, Ghosh A, Kajal K, Mahajan V, Bhalla A, Sorsa T, Raisanen I. The clinical association between Periodontitis and COVID-19. Clin Oral Investig. 2022 Feb;26(2):1361-1374. doi: 10.1007/s00784-021-04111-3. Epub 2021 Aug 27.

    PubMed 34448073
  • Hajishengallis G, Chavakis T, Lambris JD. Current understanding of periodontal disease pathogenesis and targets for host-modulation therapy. Periodontol 2000. 2020 Oct;84(1):14-34. doi: 10.1111/prd.12331.

    PubMed 32844416

Questions about this trial

What is this clinical trial studying?

An observational study of Post COVID-19 Condition, run by Ain Shams University.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 10 inclusion and 7 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: status not confirmed, as of the sponsor's last update on 18 Jul 2023. Status can change between updates, so confirm with the study contact before making plans.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

Results are not available in the source record.

How can a doctor refer a patient or contact the research team?

Contact RANDA N. ALZOUBI, Master (1554391506 ext. 0020, RANDAALZOUBI@dent.asu.edu.eg), or a site near the patient. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Clinical Assessment (time frame: Baseline). The study lists 2 primary outcomes in all. It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT05950230, which also lists 40 linked publications.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 18 Jul 2023.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in